When was Amoeba founded?

Amoeba was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Where is Amoeba located?

Amoeba is headquartered in Chassieu, France.

How many employees does Amoeba have?

As of May 31, 2026, the latest employee count at Amoeba is 1.

Is Amoeba a funded company?

Amoeba is a funded company, having raised a total of $6.49M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 2011.

When was the latest funding round of Amoeba?

Amoeba's latest funding was a $***** Post IPO round on May 13, 2016, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In France, the Life Sciences Platforms and Tools sector has seen $13.2M in funding in 2026 to date.

Where does Amoeba rank among its competitors?

Amoeba ranks 551st amongst 1957 active competitors, of which 452 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Amoeba?

Amoeba's top competitors include Synthego, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

Amoeba - 2026 Company Profile, Team, Funding & Competitors

Company Details

Amoeba is a biotechnology company based in Lyon, France that has developed and commercialized a naturally occurring amoeba, Willaertia magna, as a safe and environmentally friendly biocide. W. magna is a water-borne amoeba species that is found in hot springs and is a potent phagocytic predator against pathogenic bacteria that thrive in industrial water environments, such as Legionella, Listeria, Pseudomonas, etc. as well as other amoeba species like Acanthamoeba, Hartmanella, Naegleria sp. The biocide technology using W. magna is patent protected worldwide. The company is currently working to procure permissions to deploy its technology in countries outside the EU.

Website: amoeba-biocide.com
Social
Email ID: *****@amoeba-biocide.com

Key Metrics

Founded Year

2010

Location

Chassieu, France

Stage

Public

Total Funding

$6.49M in 4 rounds

Latest Funding Round

Post IPO, May 13, 2016, $*****

Investors

Siparex & 7 more

Ranked

551^st among 1957 active competitors

Employee Count

1 as on May 31, 2026

Similar Companies

Synthego & 2666 more

Exit Details

Public

View Amoeba's full profile

Amoeba got listed on Sep 14, 2020.

Click here to take a look at Amoeba's IPO in detail

Amoeba has raised a total funding of $6.49M over 4 rounds. Its first funding round was on Apr 2011. Amoeba has 8 institutional investors.

Here is the list of recent funding rounds of Amoeba:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 13, 2016	6499026	Post IPO	7671512	2991930	5230074	9037310
May 06, 2014	9316634	Series A	7247490	5929928	9134011	Siparex & 4 more
Oct 11, 2012	7495271	Seed	1389513	1981622	9841956	EUREKAP! & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Amoeba's funding rounds and investors

The founders of Amoeba is Fabrice Plasson.

Here are the details of Amoeba's key team members:

Fabrice Plasson: Co-Founder & President of Amoeba.

View details of Amoeba's Founder profiles and Board Members

Amoeba's employee count trend

Amoeba has 1 employees as of May 26. Here is Amoeba's employee count trend over the years:

Uncover Amoeba's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Amoeba include Synthego, Antheia and Transcenta. Here is the list of Top 10 competitors of Amoeba, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, Perceptive Advisors & 30 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Judges Scientific 2002, London (United Kingdom), Public	Acquisition and development of scientific instrument businesses	-	Origin Capital, Lloyds Banking Group	65/100
5th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
6th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Fidelity Investments ... & 14 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Bpifrance & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	UBS, Brown Brothers Harriman & 1 others	63/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$346M	Maverick Ventures, Polaris Partners & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
551st	Amoeba 2010, Chassieu (France), Public	Using a water-borne amoeba as an industrial biocide	$6.49M	Siparex, Elaia & 6 others	33/100